目的:探讨控释前列腺素E2栓剂-欣普贝生用于足月促宫颈成熟的有效性及安全性。方法:对116例孕周超过40周、Bishop宫颈评分<6分、无妊娠合并症、单胎、头位并要求阴道试产的初孕妇,以阴道放置欣普贝生促宫颈成熟作为研究组,另选78例同样条件的初孕妇用催产素促宫颈成熟作为对照组。比较两组孕妇的Bishop评分变化、临产情况及分娩的发生时间、剖宫产率、对胎儿及新生儿的影响。结果:研究组孕妇给药后,24 h后68例直接进入产程,其余40例Bishop评分提高≥2分,而对照组仅2例进入产程,28例Bishop评分提高≥2分,两组比较,差异有统计学意义(P<0.01)。研究组从给药到临产的时间为(13±4.5)h,对照组为(32±10.5)h,两组比较,差异有统计学意义(P<0.01)。研究组的剖宫产率为32.1%,而对照组则为48.1%。结论:欣普贝生可安全、有效地用于足月促宫颈成熟。 OBJECTIVE: To investigate the efficacy and safety of controlled release prostaglandin E2 suppository-Enbubese for cervical ripening at term. Methods: A total of 116 pregnant women with gestational age over 40 weeks, Bishop cervical score <6, pregnant women with no pregnancy complications, single fetus and head position requiring vaginal trial, , Another 78 cases of the same conditions of the first pregnant women with oxytocin promote cervical maturation as a control group. The changes of Bishop score, labor status and delivery time, cesarean section rate, fetus and newborn in both groups were compared. Results: In the study group, 68 pregnant women directly entered the labor process 24 hours later, the other 40 patients had a Bishop score ≥2 points, while only 2 patients in the control group entered the labor process, 28 cases had a Bishop score ≥2 points. In the two groups, The difference was statistically significant (P <0.01). The time from administration to labor was (13 ± 4.5) h in the study group and (32 ± 10.5) h in the control group. There was significant difference between the two groups (P <0.01). The cesarean section rate in the study group was 32.1%, compared with 48.1% in the control group. Conclusions: Enbubest is safe and effective for term maturation of cervix.